Zai Lab's Q3 2025 results reflect strong advancements in its clinical pipeline, particularly the promising early data for Zoci, while the company's commercial operations in China demonstrate steady growth despite a complex environment.

• Zoci (ZL-1310) shows a 68% overall response rate and 94% disease control rate in heavily pretreated extensive stage small cell lung cancer patients, suggesting strong efficacy potential.
• The company is on track for its first global approval by 2027 or early 2028, with ongoing enrollment in registrational Phase III trials.
• Zai Lab reports continued profitability within its commercial business in China, although growth is at a slower pace than anticipated amid a dynamic market.
• Significant advancements in the pipeline include the entry of IL-13/IL-31 bispecific antibody into Phase I and continued progress with innovative assets and late-stage programs.
• The company emphasizes a commitment to delivering impactful therapies and long-term value for shareholders while navigating regulatory and competitive challenges.